RE:RE:RE:RE:RE:A rare intelligent post on "the other board"The company is only a few years old and is rapidly growing through acquisitions and it has a wildcard in BC. Given how quickly things can change drastically (think Global) and that they are reinvesting $ for growth, a P/E analysis is not useful IMO. But, to me it is all guessing. I cannot comprehend the changes to PGs forecast after acquiring Global, and he surely did not offer much of a reconciliation. I recognize that most on these social forums don't really bother thinking about things but are just impressed by shiny objects thrown their way.
navajojoe wrote: canyousayiii wrote: I don't think P/E analysis is particularly useful or applicable for a company like KNR at its current life-cycle stage.
I am not sure what you mean by "current life-cycle stage", but KNR provided 2022 guidance for revenue and ebitda, which can be used in fundamental analysis. Putting a P/E multiple of 30 on KNR is about right, IMO, for a company that is growing steadily. Using ebitda in place of earnings, when earnings guidance is lacking, is not the most accurate assumption, but in the case of KNR, is just a moderately generous ball-park number.
We have to put a realistic value on the company, and the above is far more useful that 99% of the ridiculous krap we have seen posted over the last year.
Of course, BioCloud can change everything, if we get material sales. IF